drugset
drugset / Trial / NCT06888037

Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer

NCT06888037 ↗

Phase 2 Not yet recruiting 55 enrolled Ruijin Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study was designed to explore the efficacy and safety of fruquintinib combined with PD-1 inhibitors as first-line maintenance therapy for advanced HER-2 Negative Gastric Cancer.

Timeline

Start
2025-03-31
Primary completion
2028-03-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule 3 mg Oral
Background Capecitabine Small molecule 1000 mg/m2 Oral
Background Initial treatment: PD-1+ Oxaliplatin-based chemotherapy (CAPOX/SOX/FOLFOX） Unknown 3 mg/kg —
Background Initial treatment: PD-1+ Oxaliplatin-based chemotherapy (CAPOX/SOX/FOLFOX） Unknown 200 mg —
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Nivolumab Monoclonal antibody 240 mg Intravenous
Background Nivolumab Monoclonal antibody 360 mg Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous
Background Pembrolizumab Monoclonal antibody 200 mg Intravenous
Background S-1 Small molecule 40 mg Oral
Background S-1 Small molecule 60 mg Oral
Background Tislelizumab Monoclonal antibody 200 mg Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

gastric adenocarcinoma gastroesophageal junction adenocarcinoma